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When cervical screening is delivered systematically as an
organised programme, cervical cancer rates have fallen.1 Even
with the introduction of vaccination against human
papillomavirus (HPV), which can deliver high levels of
protection against cervical cancer, and other HPV related
cancers, screening remains important to reduce cervical cancer
rates in unimmunised women as well as the risk of cancers
attributed to non-vaccine HPV types in all women.
As screening has evolved over time and in different settings, so
has our understanding of the clinical course of cervical disease.
In this week’s issue, a systematic review and meta-analysis by
Tainio and colleagues (doi:10.1136/bmj.k499) provides a more
robust prediction of the clinical course and risk of active
surveillance for women with cervical intraepithelial neoplasia
grade 2 (CIN2).2 The results not only update the available
evidence but take on the challenges of bias and other limitations
in previous observational studies and trials.
Accurate figures for regression and progression are important
for our understanding of the clinical course of CIN2 and for
women who need the best possible information before choosing
between immediate treatment and surveillance. Tainio and
colleagues report that over two years, CIN2 will regress in 50%
of women kept under surveillance, persist in 32%, and progress
to CIN3 or worse in 18%. Outcomes were more favourable for
women aged less than 30 (60%, 23%, and 11%, respectively).
Cervical screening offers a relatively non-invasive test with a
reasonable performance profile that can detect early changes in
the cervix; cervical intraepithelial neoplasia (CIN). Often called
a “precancer,” CIN may be better understood as HPV induced
disease, which has the potential to progress to cancer but might
also regress completely or persist as CIN.
Over time, screening has become more sophisticated and the
bar for treatment has been raised to protect women, particularly
young women, from the reproductive harms associated with
local excision of CIN.3 4 Tainio and colleagues conclude that
CIN2 lesions should be below that bar, managed instead with
active surveillance.
Within clinical practice, and in this review, we are reliant on a
histological diagnosis to establish the grade of CIN: 1, 2, or 3.
Programmes with inbuilt quality assurance aim to improve
consistency, but variability in diagnosis within and between
observers is well documented.5 Hence the increasing interest in
biomarkers to help distinguish truly progressive CIN from
regressive disease.6
So what does this meta-analysis mean for women trying to
decide which management option is best after a CIN2 diagnosis?
Knowing that the chance of regression is 50-60%, still means
taking a gamble that surveillance is simply delaying treatment.
Even a small risk of cancer (0.5% in this study) may still be
unacceptable to some.
Women may assume the diagnosis of CIN2 is accurate and that
the risk profile presented here is reliable, but the review had
limitations, seen with the heterogeneity of the studies included
(which improved when the authors grouped studies by decade
or continent), the likelihood of misclassification, and a high risk
of bias in half the studies. The effects of local excision, such as
pain, bleeding, or menstrual disturbance,7 time off work, and
the possibility of pregnancy complications, including preterm
birth and mid-trimester miscarriage are also important
considerations in decision making.
The authors looked at progression of cervical lesions from three
months after diagnosis, but data on the duration of “active
surveillance” was limited. Active surveillance is inconvenient
for women, who must attend clinics for repeat assessments and
colposcopy. We do not yet have a clear definition of active
surveillance in the context of CIN2; which interventions and at
what frequency are needed to confirm regression, identify
persistence, or recommend treatment for progression?
In practice, there will be a range of approaches, including
“passive surveillance,” and surveillance strategies that use
cytology, HPV testing, colposcopy, or repeat biopsies either
alone or in combination. The intensity of surveillance on offer
will vary among healthcare settings and might reflect patient
or clinician preference, local policy, or local resources. It might
also depend on women’s ability to access surveillance and attend
clinics. Where women cannot afford choice, a 50% rate of
persistence or progression may justify immediate treatment of
CIN2 in women aged more than 30 years.
Inevitably, the known outcomes studied in the meta-analysis
by Tainio and colleagues do not always reflect the concerns
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most important to women. Knowledge of the rates of regression
from CIN2 are reassuring but they must be presented in a
meaningful way alongside clear information about the effects
of both surveillance and treatment, so women can make fully
informed choices. Although this meta-analysis might not have
all the answers, it does provide the best information to date on
likelihood of regression or progression after a diagnosis of CIN2.
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